Bristol-Myers Squibb Co
BMY49.750USD
-0.925-1.82%
Cierre 06/13, 16:00（ET）Cotizaciones retrasadas 15 min
101.24BCap. mercado
PérdidaP/E TTM
Más Datos de Bristol-Myers Squibb Co Compañía
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Información de la empresa
Símbolo de cotizaciónBMY
Nombre de la empresaBristol-Myers Squibb Co
Fecha de salida a bolsaMar 17, 1980
Fundada en1933
Director ejecutivoDr. Christopher S. (Chris) Boerner, Ph.D.
Número de empleados34100
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 17
DirecciónRoute 206 And Province Line Road
CiudadPRINCETON
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal08543
Teléfono16092524621
Sitio Webhttps://www.bms.com
Símbolo de cotizaciónBMY
Fecha de salida a bolsaMar 17, 1980
Fundada en1933
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
83.51K
+5.36%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.32K
+65.81%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
83.51K
+5.36%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.32K
+65.81%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
34.10B
70.61%
International
13.20B
27.33%
other
996.00M
2.06%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
Estadísticas de accionistas
Actualizado: lun., 19 de may
Actualizado: lun., 19 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.36%
BlackRock Institutional Trust Company, N.A.
4.80%
State Street Global Advisors (US)
4.66%
JP Morgan Asset Management
3.43%
Capital International Investors
3.27%
Other
74.48%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.36%
BlackRock Institutional Trust Company, N.A.
4.80%
State Street Global Advisors (US)
4.66%
JP Morgan Asset Management
3.43%
Capital International Investors
3.27%
Other
74.48%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
37.99%
Investment Advisor/Hedge Fund
33.73%
Research Firm
3.21%
Pension Fund
2.37%
Bank and Trust
2.19%
Sovereign Wealth Fund
1.87%
Hedge Fund
0.61%
Insurance Company
0.19%
Family Office
0.06%
Other
17.78%
Participación institucional
Actualizado: dom., 19 de ene
Actualizado: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
4219
1.65B
81.22%
+21.37M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
2022Q4
4105
1.66B
77.92%
-72.60M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
189.02M
9.29%
+1.40M
+0.75%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
97.01M
4.77%
-7.46M
-7.14%
Dec 31, 2024
State Street Global Advisors (US)
95.14M
4.68%
+2.25M
+2.42%
Dec 31, 2024
JP Morgan Asset Management
63.10M
3.1%
+12.35M
+24.34%
Dec 31, 2024
Capital International Investors
45.87M
2.25%
+3.22M
+7.55%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
60.30M
2.96%
-729.93K
-1.20%
Dec 31, 2024
Geode Capital Management, L.L.C.
44.39M
2.18%
+1.19M
+2.75%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
28.50M
1.4%
+12.26M
+75.55%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
First Trust NASDAQ Pharmaceuticals ETF
6.67%
ETC 6 Meridian Mega Cap Equity ETF
5.21%
Invesco S&P Ultra Dividend Revenue ETF
4.94%
ETC 6 Meridian Hedged Equity Index Option ETF
4.88%
Tema Oncology ETF
3.96%
iShares U.S. Pharmaceuticals ETF
3.77%
Schwab U.S. Dividend Equity ETF
3.49%
VictoryShares Free Cash Flow ETF
3.45%
Cullen Enhanced Equity Income ETF
3.29%
VanEck Pharmaceutical ETF
3.12%
Ver más
First Trust NASDAQ Pharmaceuticals ETF
Proporción6.67%
ETC 6 Meridian Mega Cap Equity ETF
Proporción5.21%
Invesco S&P Ultra Dividend Revenue ETF
Proporción4.94%
ETC 6 Meridian Hedged Equity Index Option ETF
Proporción4.88%
Tema Oncology ETF
Proporción3.96%
iShares U.S. Pharmaceuticals ETF
Proporción3.77%
Schwab U.S. Dividend Equity ETF
Proporción3.49%
VictoryShares Free Cash Flow ETF
Proporción3.45%
Cullen Enhanced Equity Income ETF
Proporción3.29%
VanEck Pharmaceutical ETF
Proporción3.12%
Dividendos
Un total de
22.71B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
